[1] Yang H, Lopina ST, DiPersio LP, et al.  Stealth dendrimers for drug delivery: correlation between PEGylation, cytocompatibility, and drug payload[J]. J Mater Sci Mater Med, 2008, 19(5): 1991-1997.   doi: 10.1007/s10856-007-3278-0
[2] He XD, Alves CS, Oliveira N, et al.  RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells[J]. Colloids Surf B Biointerfaces, 2015, 125: 82-89.   doi: 10.1016/j.colsurfb.2014.11.004
[3] Zeng Y, Kurokawa Y, Win-Shwe TT, et al.  Effects of PAMAM dendrimers with various surface functional groups and multiple generations on cytotoxicity and neuronal differentiation using human neural progenitor cells[J]. J Toxicol Sci, 2016, 41(3): 351-370.   doi: 10.2131/jts.41.351
[4] Asimakopoulos P, Nixon IJ, Shaha AR.  Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes[J]. Clin Oncol (R Coll Radiol), 2017, 29(5): 283-289.   doi: 10.1016/j.clon.2017.01.001
[5]

Trimboli P, Castellana M, Virili C, et al. Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis[J/OL]. Front Endocrinol (Lausanne), 2018, 9: 224 [2018-11-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943569. DOI: 10.3389/fendo.2018.00224.
[6]

Cappagli V, Potes CS, Ferreira LB, et al. Calcitonin receptor expression in medullary thyroid carcinoma[J/OL]. PeerJ, 2017, 5: e3778[2018-11-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600720. DOI: 10.7717/peerj.3778.
[7] Valderrabano P, Klippenstein DL, Tourtelot JB, et al.  New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis[J]. Thyroid, 2016, 26(8): 1093-1100.   doi: 10.1089/thy.2016.0196
[8] Wells SA Jr, Asa SL, Dralle H, et al.  Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma[J]. Thyroid, 2015, 25(6): 567-610.   doi: 10.1089/thy.2014.0335
[9] Trimboli P, Treglia G, Guidobaldi L, et al.  Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis[J]. Clin Endocrinol (Oxf), 2015, 82(2): 280-285.   doi: 10.1111/cen.12563
[10] Chauhan AS, Jain NK, Diwan PV.  Pre-clinical and behavioural toxicity profile of PAMAM dendrimers in mice[J]. Proc Roy Soc A, 2009, 466(2117): 1535-1550.   doi: 10.1098/rspa.2009.0448
[11] Nabavizadeh F, Fanaei H, Imani A, et al.  Evaluation of Nanocarrier Targeted Drug Delivery of Capecitabine-PAMAM Dendrimer Complex in a Mice Colorectal Cancer Model[J]. Acta Med Iran, 2016, 54(8): 485-493.
[12]

Vidal F, Vásquez P, Cayumán FR, et al. Prevention of Synaptic Alterations and Neurotoxic Effects of PAMAM Dendrimers by Surface Functionalization[J/OL]. Nanomaterials (Basel), 2017, 8(1): 7[2018-11-30]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791094. DOI: 10.3390/nano8010007.
[13] Tomalia DA, Baker H, Dewald J, et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules[J]. Polym J, 1985, 17(1): 117-132.   doi: 10.1295/polymj.17.117
[14] Kondo M, Asai T, Katanasaka Y, et al.  Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase[J]. Int J Cancer, 2004, 108(2): 301-306.   doi: 10.1002/ijc.11526
[15] Genís L, Gálvez BG, Gonzalo P, et al.  MT1-MMP: Universal or particular player in angiogenesis?[J]. Cancer Metastasis Rev, 2006, 25(1): 77-86.   doi: 10.1007/s10555-006-7891-z
[16] Davaa E, Lee J, Jenjob R, et al.  MT1-MMP Responsive Doxorubicin Conjugated Poly (lactic-co-glycolic Acid) /Poly (styrene-alt-maleic Anhydride) Core/Shell Microparticles for Intrahepatic Arterial Chemotherapy of Hepatic Cancer[J]. ACS Appl Mater Interfaces, 2017, 9(1): 71-79.   doi: 10.1021/acsami.6b08994
[17] He R, Wang H, Su Y, et al.  Incorporating 131I into a PAMAM (G5.0) dendrimer-conjugate: design of a theranostic nanosensor for medullary thyroid carcinoma[J]. RSC Adv, 2017, 7(26): 16181-16188.   doi: 10.1039/C7RA00604G
[18] Böckmann M, Hilken G, Schmidt A, et al.  Novel Sresphp Peptide Mediates Specific Binding to Primary Medullary Thyroid Carcinoma After Systemic Injection[J]. Hum Gene Ther, 2005, 16(11): 1267-1275.   doi: 10.1089/hum.2005.16.1267
[19] Schmidt A, Eipel C, Fürst K, et al.  Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models[J]. Gene Ther, 2011, 18(4): 418-423.   doi: 10.1038/gt.2010.165
[20] 陈礼林, 谢丽君, 张海波, 等.  靶向肽结合131I-PAMAM (G5.0)抑制甲状腺髓样癌细胞增殖的研究[J]. 国际放射医学核医学杂志, 2017, 41(5): 307-313.   doi: 10.3760/cma.j.issn.1673-4114.2017.05.001
Chen LL, Xie LJ, Zhang HB, et al.  Effects of targeted peptide-conjugated 131I-PAMAM (G5.0) on the inhibition of medullary thyroid carcinoma cells proliferation[J]. Int J Radiat Med Nucl Med, 2017, 41(5): 307-313.   doi: 10.3760/cma.j.issn.1673-4114.2017.05.001
[21] Matsuura S, Katsumi H, Suzuki H, et al.  L-Serine-modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier[J]. Proc Natl Acad Sci USA, 2018, 115(41): 10511-10516.   doi: 10.1073/pnas.1808168115
[22] Cui W, Zhang YQ, Xu XP, et al.  Synthesis and 188Re Radiolabelling of Dendrimer Polyamide Amine (PAMAM) Folic Acid Conjugate[J]. Med Chem, 2012, 8(4): 727-731.   doi: 10.2174/157340612801216256
[23] 王立, 薛冰, 张文君, 等.  聚酰胺-胺型树枝状大分子的应用研究[J]. 哈尔滨商业大学学报: 自然科学版, 2018, 34(1): 24-26, 48.   doi: 10.3969/j.issn.1672-0946.2018.01.007
Wang L, Xue B, Zhang WJ, et al.  Advances in application of polyamide-amine dendrimers[J]. J Harbin Univ Commer: Nat Sci Ed, 2018, 34(1): 24-26, 48.   doi: 10.3969/j.issn.1672-0946.2018.01.007